Close

Volitionrx Limited (VNRX) Announces Presentation of Positive Blood Test for Colorectal Cancer Data

Go back to Volitionrx Limited (VNRX) Announces Presentation of Positive Blood Test for Colorectal Cancer Data

Data Presented at ESMO 2016 Demonstrates that VolitionRx Limited's Novel Blood Test for Colorectal Cancer Potentially Reduces the Need for Colonoscopy Referral by 25%

October 11, 2016 8:30 AM EDT

NAMUR, Belgium, Oct. 11, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer, today announced that research presented at the European Society for Medical Oncology Congress (ESMO) shows that Volition's novel blood test for colorectal cancer combined with the conventional faecal immunochemical screening test has the potential to offer up to a 25% reduction in colonoscopies while maintaining almost 97% detection of colorectal cancer when combined with the faecal immunochemical test (FIT) score.

Dr. Marielle Herzog, Volition's lead scientist for Nucleosomics®,... More